The Cigna Group (CI)
| Market Cap | 87.17B |
| Revenue (ttm) | 255.37B |
| Net Income (ttm) | 5.03B |
| Shares Out | 267.14M |
| EPS (ttm) | 17.99 |
| PE Ratio | 18.14 |
| Forward PE | 10.51 |
| Dividend | $6.04 (1.85%) |
| Ex-Dividend Date | Jun 3, 2025 |
| Volume | 3,402,334 |
| Open | 329.00 |
| Previous Close | 330.00 |
| Day's Range | 325.96 - 332.57 |
| 52-Week Range | 262.03 - 370.83 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 386.76 (+18.53%) |
| Earnings Date | Jul 31, 2025 |
About CI
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company’s Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other product... [Read more]
Financial Performance
In 2024, The Cigna Group's revenue was $247.12 billion, an increase of 26.56% compared to the previous year's $195.27 billion. Earnings were $3.43 billion, a decrease of -33.50%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for CI stock is "Strong Buy." The 12-month stock price forecast is $386.76, which is an increase of 18.53% from the latest price.
News
Cigna Enables Coverage for RhinAer®
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinA...
The Cigna Group's Second Quarter 2025 Earnings Release Details
BLOOMFIELD, Conn. , June 25, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) will release its second quarter 2025 financial results on Thursday, July 31, 2025, and will host a co...
Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst
Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.
US health chief Kennedy met with insurers on prior authorization requirements
U.S. health secretary Robert F. Kennedy Jr. met with major health insurers on Monday, extracting pledges that they will take additional measures to simplify their requirements for prior approval on me...
Cigna: Valuation Discount To Historical And Sector Averages Persists
Cigna has transformed into a diversified healthcare platform, focusing on high-margin corporate insurance and pharmacy services while divesting non-core assets. Despite margin pressures, Cigna's servi...
Wake Up Wall Street - 2 Massively Mispriced Dividend Gems
I believe the odds favor long-term market gains. Analysts' optimism supports my view that overlooked areas offer the best opportunities now. That's why I'm focusing on two dividend stocks with rising ...
Cigna Healthcare Unveils Industry-Leading AI-Powered Digital Tools for a Simple and Reliable Customer Experience
New features blend innovation, responsible AI, and human interactions to better support customers in their health care journeys As new data show 4 out of 5 U.S. adults don't feel confident in their kn...
The Cigna Group Health Equity Impact Fund Opens 2025 Grants
The Fund will distribute another $3 million to nonprofits to improve health outcomes BLOOMFIELD, Conn. , June 4, 2025 /PRNewswire/ -- The Cigna Group Foundation today announced the second year of gran...
The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors
BLOOMFIELD, Conn. , June 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Michael J.
Cigna Adds Kerecis Intact Fish-Skin Grafts to Coverage Policy
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)-- #kerecis--Cigna Insurance Company now includes Kerecis products in its medical coverage policy for the treatment of diabetic foot ulcers.
Cigna to offer $200 Wegovy, Zepbound weight-loss benefit
Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more than $200 a month out-of-pocket for weight-loss drugs Wegovy and Zepbound.
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket costs ...
Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month
Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible New offering helps employers meet growing demand ...
Our Top 10 High-Growth Dividend Stocks -- May 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Cigna and CVS shares fall as Trump targets ‘middlemen' in sweeping executive order against Big Pharma
The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.
Trump's drug pricing order delivers blow to pharmacy benefit managers
President Donald Trump on Monday delivered a blow to the private-sector middlemen who negotiate U.S. drug prices in his executive order on drug pricing, saying he would cut them out as part of a goal ...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
The Best Health Care Stocks to Buy
The best health care stocks offer investors a defensive hedge in an uncertain market. Here's how to find them.
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (May 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
The Cigna Group (CI) Q1 2025 Earnings Call Transcript
The Cigna Group (NYSE:CI) Q1 2025 Earnings Conference Call May 2, 2025 8:30 AM ET Company Participants Ralph Giacobbe - Senior Vice President, Investor Relations David Cordani - Chairman and Chief Ex...
Cigna CEO Says Strong Q1 Earnings, Increased Outlook Reflect Strength In Growth Platforms
Cigna Group CI on Friday reported first-quarter 2025 revenue of $65.45 billion, beating analyst estimates of $60.39 billion.
Cigna Group Swings to Profit, Posts Higher Revenue
Cigna Group swung to a profit and logged higher revenue in the first quarter, prompting the company to raise its full-year outlook.
Cigna raises full-year profit forecast, latest to beat medical cost estimates
Cigna on Friday raised its full-year earnings forecast and beat estimates for quarterly profit, helped by strong performance in its pharmacy benefit management business and lower-than-expected medical...
The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook
Total revenues for the first quarter 2025 increased 14% to $65.5 billion Shareholders' net income for the first quarter 2025 was $1.3 billion, or $4.85 per share Adjusted income from operations1 for t...
Cigna Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
The Cigna Group CI will release earnings results for the first quarter, before the opening bell on Friday, May 2.